dc.contributor.author | Privitera, L | |
dc.contributor.author | Waterhouse, DJ | |
dc.contributor.author | Preziosi, A | |
dc.contributor.author | Paraboschi, I | |
dc.contributor.author | Ogunlade, O | |
dc.contributor.author | Da Pieve, C | |
dc.contributor.author | Barisa, M | |
dc.contributor.author | Ogunbiyi, O | |
dc.contributor.author | Weitsman, G | |
dc.contributor.author | Hutchinson, JC | |
dc.contributor.author | Cross, K | |
dc.contributor.author | Biassoni, L | |
dc.contributor.author | Stoyanov, D | |
dc.contributor.author | Sebire, N | |
dc.contributor.author | Beard, P | |
dc.contributor.author | De Coppi, P | |
dc.contributor.author | Kramer-Marek, G | |
dc.contributor.author | Anderson, J | |
dc.contributor.author | Giuliani, S | |
dc.coverage.spatial | United States | |
dc.date.accessioned | 2023-06-07T10:11:15Z | |
dc.date.available | 2023-06-07T10:11:15Z | |
dc.date.issued | 2023-06-15 | |
dc.identifier | 718789 | |
dc.identifier.citation | Cancer Research, 2023, pp. CAN-22-2918 - | |
dc.identifier.issn | 0008-5472 | |
dc.identifier.uri | https://repository.icr.ac.uk/handle/internal/5835 | |
dc.identifier.eissn | 1538-7445 | |
dc.identifier.eissn | 1538-7445 | |
dc.identifier.doi | 10.1158/0008-5472.CAN-22-2918 | |
dc.description.abstract | UNLABELLED: Fluorescence-guided surgery is set to play a pivotal role in the intraoperative management of pediatric tumors. Shortwave infrared imaging (SWIR) has advantages over conventional near-infrared I (NIR-I) imaging with reduced tissue scattering and autofluorescence. Here, two NIR-I dyes (IRDye800CW and IR12), with long tails emitting in the SWIR range, were conjugated with a clinical-grade anti-GD2 monoclonal antibody (dinutuximab-beta) to compare NIR-I and SWIR imaging for neuroblastoma surgery. A first-of-its-kind multispectral NIR-I/SWIR fluorescence imaging device was constructed to allow an objective comparison between the two imaging windows. Conjugates were first characterized in vitro. Tissue-mimicking phantoms, imaging specimens of known geometric and material composition, were used to assess the sensitivity and depth penetration of the NIR-I/SWIR device, showing a minimum detectable volume of ∼0.9 mm3 and depth penetration up to 3 mm. In vivo, fluorescence imaging using the NIR-I/SWIR device showed a high tumor-to-background ratio (TBR) for both dyes, with anti-GD2-IR800 being significantly brighter than anti-GD2-IR12. Crucially, the system enabled higher TBR at SWIR wavelengths than at NIR-I wavelengths, verifying SWIR imaging enables high-contrast delineation of tumor margins. This work demonstrates that by combining the high specificity of anti-GD2 antibodies with the availability and translatability of existing NIR-I dyes, along with the advantages of SWIR in terms of depth and tumor signal-to-background ratio, GD2-targeted NIR-I/SWIR-guided surgery could improve the treatment of patients with neuroblastoma, warranting investigation in future clinical trials. SIGNIFICANCE: Multispectral near-infrared I/shortwave infrared fluorescence imaging is a versatile system enabling high tumor-to-background signal for safer and more complete resection of pediatric tumors during surgery. | |
dc.format | Print-Electronic | |
dc.format.extent | CAN-22-2918 - | |
dc.language | eng | |
dc.language.iso | eng | |
dc.publisher | AMER ASSOC CANCER RESEARCH | |
dc.relation.ispartof | Cancer Research | |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Shortwave Infrared Imaging Enables High-Contrast Fluorescence-Guided Surgery in Neuroblastoma. | |
dc.type | Journal Article | |
dcterms.dateAccepted | 2023-03-08 | |
dc.date.updated | 2023-06-07T10:10:49Z | |
rioxxterms.version | VoR | |
rioxxterms.versionofrecord | 10.1158/0008-5472.CAN-22-2918 | |
rioxxterms.licenseref.startdate | 2023-03-19 | |
rioxxterms.type | Journal Article/Review | |
pubs.author-url | https://www.ncbi.nlm.nih.gov/pubmed/36934744 | |
pubs.organisational-group | /ICR | |
pubs.organisational-group | /ICR/Primary Group | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Cancer Therapeutics/Preclinical Molecular Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging | |
pubs.organisational-group | /ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Preclinical Molecular Imaging | |
pubs.publication-status | Published online | |
pubs.publisher-url | http://dx.doi.org/10.1158/0008-5472.can-22-2918 | |
icr.researchteam | Preclin Molecular Imaging | |
dc.contributor.icrauthor | Da Pieve, Chiara | |
dc.contributor.icrauthor | Kramer-Marek, Gabriela | |
icr.provenance | Deposited by Mr Arek Surman on 2023-06-07. Deposit type is initial. No. of files: 1. Files: can-22-2918.pdf | |